INFECTIONS IN ADULT LIVER-TRANSPLANT PATIENTS UNDER FK506 IMMUNOSUPPRESSION

被引：0
|
作者：
ALESSIANI, M
KUSNE, S
MARTIN, M
JAIN, A
ABUELMAGD, K
MOSER, J
TODO, S
FUNG, J
STARZL, T
机构：
[1] UNIV PITTSBURGH,CTR HLTH,DEPT SURG,PITTSBURGH,PA 15260
[2] VET ADM MED CTR,PITTSBURGH,PA
[3] UNIV PITTSBURGH,CTR HLTH,DEPT MED,PITTSBURGH,PA 15260
来源：
TRANSPLANTATION PROCEEDINGS | 1991年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1501 / 1503
页数：3
相关论文
共 50 条
  • [21] LONG-TERM EFFECTS OF FK506 FOLLOWING CONVERSION FROM CYCLOSPORINE TO FK506 FOR CHRONIC REJECTION IN LIVER-TRANSPLANT RECIPIENTS
    FUNG, JJ
    JAIN, A
    HAMMAD, I
    DOYLE, H
    SELBY, R
    TZAKIS, AG
    TODO, S
    STARZL, TE
    HEPATOLOGY, 1993, 18 (04) : A74 - A74
  • [22] REVERSAL OF GASTROINTESTINAL, TOXICITY ASSOCIATED WITH LONG-TERM FK506 IMMUNOSUPPRESSION BY CONVERSION TO CYCLOSPORINE IN LIVER-TRANSPLANT RECIPIENTS
    MOR, E
    SCHWERSENZ, A
    SHEINER, PA
    EMRE, S
    SCHWARTZ, ME
    MILLER, CM
    TRANSPLANTATION, 1994, 57 (07) : 1130 - 1132
  • [23] RENAL-FUNCTION IN LIVER-TRANSPLANT PATIENTS RECEIVING FK506 OR CYCLOSPORINE-A IMMUNOSUPPRESSIVE THERAPY
    FREI, U
    WAGNER, K
    TRANSPLANTATION PROCEEDINGS, 1994, 26 (06) : 3270 - 3271
  • [24] EARLY INFECTIONS IN KIDNEY-TRANSPLANT RECIPIENTS UNDER FK506
    KUSNE, S
    MARTIN, M
    SHAPIRO, R
    JORDAN, M
    FUNG, J
    ALESSIANI, M
    JAIN, A
    TODO, S
    STARZL, T
    TRANSPLANTATION PROCEEDINGS, 1991, 23 (01) : 956 - 957
  • [25] GLYCEMIA AND INSULIN NEED FOLLOWING FK506 RESCUE THERAPY IN LIVER-TRANSPLANT RECIPIENTS
    MIELES, L
    GORDON, RD
    MINTZ, D
    TOUSSAINT, RM
    IMVENTARZA, O
    STARZL, TE
    TRANSPLANTATION PROCEEDINGS, 1991, 23 (01) : 949 - 953
  • [26] SYSTEMIC AND RENAL HEMODYNAMIC DIFFERENCES BETWEEN FK506 AND CYCLOSPORINE IN LIVER-TRANSPLANT RECIPIENTS
    TEXTOR, SC
    WIESNER, R
    WILSON, DJ
    PORAYKO, M
    ROMERO, JC
    BURNETT, JC
    GORES, G
    HAY, E
    DICKSON, ER
    KROM, RA
    TRANSPLANTATION, 1993, 55 (06) : 1332 - 1339
  • [27] PHARMACOKINETICS OF FK506 IN LIVER-TRANSPLANT RECIPIENTS AFTER CONTINUOUS INTRAVENOUS-INFUSION
    JAIN, AB
    ABUELMAGD, K
    ABDALLAH, H
    WARTY, V
    FUNG, J
    TODO, S
    STARZL, TE
    VENKATARAMANAN, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (07): : 606 - 611
  • [28] Liver transplant pathology in patients with elevated FK506 levels
    Hunt, J
    Gordon, F
    Lewis, D
    Jenkins, R
    Khettry, U
    LABORATORY INVESTIGATION, 1999, 79 (01) : 163A - 163A
  • [29] LATE EFFECTS OF CYCLOSPORINE AND FK506 ON LIPID-METABOLISM IN LIVER-TRANSPLANT RECIPIENTS
    MOR, E
    ATILLASOV, E
    KREIZMAN, I
    KOLESNIKOV, V
    MORAN, V
    SCHWARTZ, B
    SHEINER, PA
    SCHWARTZ, ME
    MILLER, CM
    BERK, P
    HEPATOLOGY, 1994, 20 (04) : A123 - A123
  • [30] KIDNEY-TRANSPLANTATION UNDER FK506 IMMUNOSUPPRESSION
    SHAPIRO, R
    JORDAN, M
    FUNG, J
    MCCAULEY, J
    JOHNSTON, J
    IWAKI, Y
    TZAKIS, A
    HAKALA, T
    TODO, S
    STARZL, TE
    TRANSPLANTATION PROCEEDINGS, 1991, 23 (01) : 920 - 923
12345